Genetic and epigenetic factors shaping response in advanced myeloproliferative neoplasms
Official title: Evaluation of genetic and epigenetic determinants of response in patients with accelerated and blast phase Myeloproliferative Neoplasm (MPNs)
Funded at Sloan-Kettering Inst Can Research · NIH-11352898 · Data updated 2026-11-12
This grant looks at how genetic and epigenetic differences influence how patients with advanced myeloproliferative neoplasms respond to therapies.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 2, 2026 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $444,590 |
| NIH project number | 1R21CA313410-01 |
| Project ID | NIH-11352898 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with Philadelphia-chromosome–negative myeloproliferative neoplasms at risk of or experiencing accelerated or blast-phase progression may be eligible, particularly those who have previously received or are considered for hypomethylating agent therapy plus JAK inhibition.
✕Less likely to help
Patients without progressive disease or those not receiving hypomethylating agents or JAK inhibitors may not benefit from the findings.
What this research studies
Patients with polycythemia vera, essential thrombocytosis, or primary myelofibrosis can progress to aggressive phases of disease. The project plans to study DNA-level and epigenetic marks that may determine who benefits from treatments like hypomethylating agents and JAK inhibitors in advanced disease. Researchers will build on prior studies to analyze genetic variants, methylation patterns, and related biomarkers in affected patients. The goal is to identify factors that predict response and guide more effective, personalized treatment approaches. This work could pave the way for better outcomes in a group with historically poor survival.
Why it matters
Potential benefit: If successful, patients with advanced MPNs could receive more tailored therapies with better response rates and longer survival.
How similar studies have gone: Prior phase I/II work showed some responses with Ruxolitinib and Decitabine, supporting further exploration of biomarkers to predict who benefits.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Rampal, Raajit — Sloan-Kettering Inst Can Research
- Study coordinator: Rampal, Raajit
Related research
Other NIH-funded projects on the same topics.
-
Complement and clotting in JAK2V617F myeloproliferative neoplasms
A short, patient-friendly study will look at how a specific mutation in blood cells may trigger the body’s complement system to cause clots in people with myeloproliferative neoplasms.
-
Endothelial contribution to blood-clotting in myeloproliferative neoplasms
This project explores how the lining of blood vessels may drive dangerous clots in people with myeloproliferative neoplasms (MPNs).
-
Hypoxia-inducible factors and neutrophil diversity in blood clotting in myeloproliferative neoplasms
A physician-scientist is training over five years to uncover how low-oxygen signals and diverse neutrophils drive dangerous clots in people with myeloproliferative neoplasms, with the goal of finding new treatment targets.
-
Inherited genetic risks shaping myeloid cancer initiation
A research project at Boston Children’s Hospital is exploring how inherited genetic differences may push blood stem cells toward the start of myeloproliferative neoplasms, with potential implications for earlier detection and prevention.
-
Understanding why some myeloproliferative neoplasm patients resist interferon therapy
Researchers are studying why interferon-alpha works for some blood cancer patients but not others, by looking closely at stem cells from CALR-mutated myeloproliferative neoplasms.
-
Understanding why some patients with blood cancers don't respond to interferon-alpha treatment
This study is looking at how certain blood cancer stem cells with CALR mutations react to a treatment called interferon-alpha, to help understand why some patients improve in their blood counts but not in tumor size, which could lead to better treatments for people with blood cancers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.